Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biomerica, Inc. stock logo
BMRA
Biomerica
$3.47
+1.8%
$3.27
$2.08
$10.16
$8.84M0.26643,273 shs52,759 shs
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
$1.99
+13.7%
$1.40
$7.80
$12.38
$34.33MN/A41,322 shs837,649 shs
MAAQ
Mana Capital Acquisition
$3.64
+4.0%
$3.93
$5.35
$10.25
$29.58MN/A33,075 shs4,513 shs
Mural Oncology PLC stock logo
MURA
Mural Oncology
$2.08
+0.5%
$2.27
$0.95
$4.74
$36.03M31.99 million shs435,374 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biomerica, Inc. stock logo
BMRA
Biomerica
+6.23%-2.85%-5.28%+9.65%-2.08%
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
+1.16%+10.06%+1.74%+68.27%-50.70%
MAAQ
Mana Capital Acquisition
-4.63%-6.42%-18.60%-17.45%+677.95%
Mural Oncology PLC stock logo
MURA
Mural Oncology
-0.96%+16.95%-15.51%-24.73%-37.08%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Biomerica, Inc. stock logo
BMRA
Biomerica
0.8367 of 5 stars
0.05.00.00.02.00.80.0
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
N/AN/AN/AN/AN/AN/AN/AN/A
MAAQ
Mana Capital Acquisition
N/AN/AN/AN/AN/AN/AN/AN/A
Mural Oncology PLC stock logo
MURA
Mural Oncology
2.9824 of 5 stars
3.33.00.00.01.82.51.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Biomerica, Inc. stock logo
BMRA
Biomerica
0.00
N/AN/AN/A
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
0.00
N/AN/AN/A
MAAQ
Mana Capital Acquisition
0.00
N/AN/AN/A
Mural Oncology PLC stock logo
MURA
Mural Oncology
2.50
Moderate Buy$12.00478.31% Upside

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Biomerica, Inc. stock logo
BMRA
Biomerica
$5.68M1.56N/AN/A$3.13 per share1.11
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
N/AN/A$0.07 per share27.08($0.53) per shareN/A
MAAQ
Mana Capital Acquisition
N/AN/AN/AN/AN/AN/A
Mural Oncology PLC stock logo
MURA
Mural Oncology
N/AN/AN/AN/A$3.39 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Biomerica, Inc. stock logo
BMRA
Biomerica
-$5.98M-$2.32N/AN/A-85.42%-85.90%-61.06%8/27/2025 (Estimated)
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
$6.85MN/A0.00N/AN/A-49.58%2.84%N/A
MAAQ
Mana Capital Acquisition
N/AN/A0.00N/AN/AN/AN/AN/A
Mural Oncology PLC stock logo
MURA
Mural Oncology
-$128.51M-$8.59N/AN/AN/AN/A-107.76%-87.57%N/A

Latest BMRA, MURA, MAAQ, and JATT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/4/2025Q2 2025
Mural Oncology PLC stock logo
MURA
Mural Oncology
-$1.13-$1.77-$0.64-$2.78N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Biomerica, Inc. stock logo
BMRA
Biomerica
N/AN/AN/AN/AN/A
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
N/AN/AN/AN/AN/A
MAAQ
Mana Capital Acquisition
N/AN/AN/AN/AN/A
Mural Oncology PLC stock logo
MURA
Mural Oncology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Biomerica, Inc. stock logo
BMRA
Biomerica
N/A
3.76
2.76
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
N/A
0.15
0.15
MAAQ
Mana Capital Acquisition
N/AN/AN/A
Mural Oncology PLC stock logo
MURA
Mural Oncology
N/A
2.87
2.87

Institutional Ownership

CompanyInstitutional Ownership
Biomerica, Inc. stock logo
BMRA
Biomerica
22.28%
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
47.97%
MAAQ
Mana Capital Acquisition
68.44%
Mural Oncology PLC stock logo
MURA
Mural Oncology
80.21%

Insider Ownership

CompanyInsider Ownership
Biomerica, Inc. stock logo
BMRA
Biomerica
15.00%
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
20.00%
MAAQ
Mana Capital Acquisition
N/A
Mural Oncology PLC stock logo
MURA
Mural Oncology
2.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Biomerica, Inc. stock logo
BMRA
Biomerica
602.55 million2.16 millionOptionable
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
317.25 million13.80 millionNot Optionable
MAAQ
Mana Capital Acquisition
18.13 millionN/ANot Optionable
Mural Oncology PLC stock logo
MURA
Mural Oncology
11917.32 million16.94 millionOptionable

Recent News About These Companies

Xoma, a drug royalty specialist, buys another ‘zombie’ biotech
Two new murals installed in Downtown Peoria
From courtyard to connection: KGH welcomes a new healing mural
Mural Oncology (MURA) to Release Quarterly Earnings on Tuesday

New MarketBeat Followers Over Time

Media Sentiment Over Time

Biomerica stock logo

Biomerica NASDAQ:BMRA

$3.47 +0.06 (+1.76%)
Closing price 04:00 PM Eastern
Extended Trading
$3.42 -0.05 (-1.30%)
As of 06:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.

JATT Acquisition stock logo

JATT Acquisition NYSE:JATT

$1.99 +0.24 (+13.71%)
As of 08/21/2025

JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.

Mana Capital Acquisition NASDAQ:MAAQ

$3.64 +0.14 (+4.00%)
As of 08/21/2025

Mana Capital Acquisition Corp. focuses on engaging in a merger, stock exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. It intends to focus on businesses operating in the healthcare, technology, green economy, and consumer products sectors in North America, Europe, and Asia. The company was incorporated in 2021 and is based in Dover, Delaware.

Mural Oncology stock logo

Mural Oncology NASDAQ:MURA

$2.08 +0.01 (+0.48%)
Closing price 04:00 PM Eastern
Extended Trading
$2.07 -0.01 (-0.48%)
As of 06:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.